Sutro Biopharma, Inc.
STRO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,413,657 | $2,581,016 | $4,099,726 | $6,862,520 |
| - Cash | $190,304 | $69,268 | $47,254 | $30,414 |
| + Debt | $203,963 | $33,635 | $55,015 | $57,374 |
| Enterprise Value | $1,427,316 | $2,545,383 | $4,107,487 | $6,889,480 |
| Revenue | $62,043 | $153,731 | $67,772 | $61,880 |
| % Growth | -59.6% | 126.8% | 9.5% | – |
| Gross Profit | $54,825 | $146,915 | $59,484 | $52,107 |
| % Margin | 88.4% | 95.6% | 87.8% | 84.2% |
| EBITDA | -$180,453 | -$67,915 | -$105,070 | -$97,557 |
| % Margin | -290.9% | -44.2% | -155% | -157.7% |
| Net Income | -$227,461 | -$106,793 | -$119,204 | -$105,538 |
| % Margin | -366.6% | -69.5% | -175.9% | -170.6% |
| EPS Diluted | -29.6 | -17.8 | -23.5 | -22.9 |
| % Growth | -66.3% | 24.3% | -2.6% | – |
| Operating Cash Flow | -$191,540 | -$111,616 | $3,549 | -$81,679 |
| Capital Expenditures | -$3,098 | -$4,315 | -$7,858 | -$15,323 |
| Free Cash Flow | -$194,638 | -$115,931 | -$4,309 | -$97,002 |